Seismic Therapeutic Unveils Fresh Preclinical Efficacy Results for S-1117 in Preventive and Treatment Animal Models of Immune Thrombocytopenia at the 66th ASH Meeting.

Molecular Targeting Technologies, Inc. (MTTI) has released preclinical research findings for their proprietary 225Ac-EBTATE targeting SSTR2-positive neuroendocrine tumors (NET).

Merck Reports Phase 3 KEYLYNK-001 Study Achieves Main Goal of Progression-Free Survival in Advanced Ovarian Cancer Patients.

Molecular Partners Unveils Clinical Findings for MP0533 Study and Preclinical Insights on MP0621 at ASH 2024, Advancing Their Research Agenda.

C4 Therapeutics Reveals Phase 1 Trial Results of Cemsidomide at the ASH Annual Meeting, Highlighting Its Potential as a Leading IKZF1/3 Degrader.

Boosting Effectiveness and Security: CStone Unveils Recent Clinical Findings on CS5001 for Advanced Lymphoma at the 66th ASH Conference.

Innovent unveiled new findings from its Phase 1 trial of the novel anti-CLDN18.2 ADC (IBI343) for advanced pancreatic cancer at the ESMO Asia Congress 2024.

Merck's experimental drug Zilovertamab Vedotin combined with R-CHP achieved a complete response rate of 100% at a dosage of 1.75 mg/kg.

PureTech showcases LYT-200 (anti-galectin-9 monoclonal antibody) data for relapsed/refractory AML/MDS at the 2024 ASH Annual Meeting.

Galapagos Reveals Promising New Findings from Ongoing Phase 1/2 Trial of CD19 CAR T-Cell Treatment, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma.

The clinical trial of Epcoritamab (DuoBody® CD3xCD20) combination therapy demonstrates significant response rates in patients with relapsed or refractory follicular lymphoma (FL).

WaveBreak reveals initial preclinical results showing that the small molecule WTX-245 effectively inhibits the underlying causes of TDP-43 pathology.